ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First-Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Large B-Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy

Autor: Westin, Jason, Burke, John, Lynch, Ryan, Abramson, Jeremy, Stevens, Don, Matasar, Matthew, Fitzgerald, Lindsey, Zausner Skarbnik, Alan, Iragavarapu, Chaitanya, Essell, James, Hunter, Bradley, Merchant, Akil, Varadarajan, Indumathy, Tandra, Anand, Licitra, Edward, Bryan, Locke, Patel, Rushang D., Behl, Rajesh, Sharmann, Jeff, Holmes, Houston E., Fanning, Suzanne, Yimer, Habte, Gandhi, Mitul, Simmons, Gary, Feng, Amy, Navale, Lynn, Ghatta, Srinivas, Le Gall, John B., Herrera, Alex F.
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S251-S251
Databáze: ScienceDirect
Externí odkaz: